Last Week Of Fun In The Markets? Click to watch.

BioCryst Pharmaceuticals Stock Forecast

NASDAQ:BCRX BUY SELL

$10.58 (-2.13%)

Volume: 1.908M

Closed: Jun 30, 2022

Hollow Logo Score: 1.492

BioCryst Pharmaceuticals Stock Forecast

BUY SELL NASDAQ:BCRX
$10.58 (-2.13%)

Volume: 1.908M

Closed: Jun 30, 2022

Score Hollow Logo 1.492

BCRX Price Targets and Analyst Ratings NASDAQ:BCRX

Historical Ratings and Targets

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-04-18 22.87% Barclays $22.00 $13.00 Downgrades Overweight Equal-Weight
2022-04-12 32.33% RBC Capital $16.00 $14.00 Maintains Sector Perform
2022-04-11 51.23% Oppenheimer $20.00 $16.00 Maintains Outperform
2022-04-11 32.33% B of A Securities $14.00 Downgrades Buy Neutral
2021-12-10 51.23% Oppenheimer $16.00 Initiates Coverage On Outperform
2021-11-04 32.33% RBC Capital $16.00 $14.00 Maintains Sector Perform
2021-11-04 60.68% Barclays $21.00 $17.00 Maintains Overweight
2021-08-06 98.49% Barclays $20.00 $21.00 Maintains Overweight
2021-08-06 183.55% HC Wainwright & Co. $18.00 $30.00 Maintains Buy
2021-08-06 117.39% JMP Securities $22.00 $23.00 Maintains Market Outperform
2021-08-06 51.23% RBC Capital $13.00 $16.00 Maintains Sector Perform
2021-08-06 - Jefferies - Downgrades Buy Hold
2021-08-03 98.49% Cantor Fitzgerald $21.00 Initiates Coverage On Overweight
2021-03-24 79.58% HC Wainwright & Co. $14.00 $19.00 Maintains Buy
2021-01-22 -14.93% RBC Capital $7.00 $9.00 Maintains Sector Perform
2020-12-07 32.33% HC Wainwright & Co. $13.00 $14.00 Maintains Buy
2020-11-24 13.42% Evercore ISI Group $12.00 Initiates Coverage On Outperform
2020-06-17 - BTIG - Initiates Coverage On Neutral
2020-05-05 -33.84% Barclays $4.00 $7.00 Upgrades Equal-Weight Overweight
2019-11-15 - B of A Securities - Upgrades Neutral Buy
2019-05-24 -57.47% RBC Capital $16.00 $4.50 Downgrades Outperform Sector Perform

BCRX Stock Trend

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $10.70 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.

Given the current short-term trend, the stock is expected to fall -25.88% during the next 3 months and, with a 90% probability hold a price between $4.37 and $7.93 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2022-07-05 $5.84 $8.24 $10.64
2022-07-06 $5.78 $8.18 $10.58
2022-07-07 $5.72 $8.12 $10.52
2022-07-08 $5.66 $8.06 $10.46
2022-07-11 $5.60 $8.00 $10.40
2022-07-12 $5.54 $7.94 $10.34
2022-07-13 $5.48 $7.88 $10.28
2022-07-14 $5.42 $7.82 $10.22
2022-07-15 $5.36 $7.76 $10.16
2022-07-18 $5.30 $7.70 $10.10
2022-07-19 $5.24 $7.64 $10.04
2022-07-20 $5.18 $7.58 $9.98
2022-07-21 $5.12 $7.52 $9.92
2022-07-22 $5.06 $7.46 $9.86
2022-07-25 $5.00 $7.40 $9.80
2022-07-26 $4.94 $7.34 $9.74
2022-07-27 $4.88 $7.28 $9.68
2022-07-28 $4.82 $7.22 $9.61
2022-07-29 $4.76 $7.16 $9.55
2022-08-01 $4.70 $7.10 $9.49
2022-08-02 $4.64 $7.04 $9.43
2022-08-03 $4.58 $6.98 $9.37
2022-08-04 $4.52 $6.91 $9.31
2022-08-05 $4.46 $6.85 $9.25
2022-08-08 $4.40 $6.79 $9.19
2022-08-09 $4.34 $6.73 $9.13
2022-08-10 $4.28 $6.67 $9.07
2022-08-11 $4.21 $6.61 $9.01
2022-08-12 $4.15 $6.55 $8.95
2022-08-15 $4.09 $6.49 $8.89

IMPROVE YOUR TRADING GAME WITH A GOLDEN STAR

From 27 537 stocks, only a few dozen will trigger such a signal!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II/III clinical trial for hereditary angioedema (HAE); BCX7353, ... Read more

.

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT